1-(4'-hydroxyphenyl)-4-methylpiperazine | 163210-63-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(4'-hydroxyphenyl)-4-methylpiperazine
• 英文别名: 4-(4-methylpiperazin-1-yl)phenol；4-(4-methyl-piperazin-1-yl)-phenol；1-(p-Hydroxyphenyl)-4-methylpiperazin；Phenol, 4-(4-methyl-1-piperazinyl)-
• CAS: 163210-63-7
• 化学式: C₁₁H₁₆N₂O
• 分子量: 192.261
• InChiKey: RWDJMTACZOUIAI-UHFFFAOYSA-N

物化性质

• 沸点：
  345.7±37.0 °C(Predicted)
• 密度：
  1.123±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  26.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(4'-hydroxyphenyl)-4-methylpiperazine 在 copper(l) iodide 、 四甲基乙二胺 、 palladium 10% on activated carbon 、 氢气 、 caesium carbonate 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 27.0h， 生成 1-(3-methoxy-4-(4-(4-methylpiperazin-1-yl)phenoxy)phenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
  参考文献：
  名称：

  Potent human glutaminyl cyclase inhibitors as potential anti-Alzheimer’s agents: Structure-activity relationship study of Arg-mimetic region

  摘要：

  Pyroglutamate-modified amyloid beta peptides (pGlu-A beta) are highly neurotoxic and promote the formation of amyloid plaques. The pGlu-A beta peptides are generated by glutaminyl cyclase (QC), and recent clinical studies indicate that QC represents an alternative therapeutic target to treat Alzheimer's disease (AD). We have previously developed a series of QC inhibitors with an extended pharmacophoric scaffold, termed the Arg-mimetic D-region. In the present study, we focused on the structure activity relationship (SAR) of analogues with modifications in the D-region and evaluated their biological activity. Most compounds in this series exhibited potent activity in vitro, and our SAR analysis and the molecular docking studies identified compound 202 as a potential candidate because it forms an additional hydrophobic interaction in the hQC active site. Overall, our study provides valuable insights into the Arg-mimetic pharmacophore that will guide the design of novel QC inhibitors as potential treatments for AD. (C) 2018 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2018.01.015
• 作为产物：
  描述：

  在 4-甲基苯磺酸吡啶 作用下， 以 乙醇 为溶剂， 反应 24.0h， 生成 1-(4'-hydroxyphenyl)-4-methylpiperazine
  参考文献：
  名称：

  N-（2-苯氧基）乙基咪唑并[1,2 - a ]吡啶-3-羧酰胺类新型抗结核药的设计，合成及生物学活性

  摘要：

  根据在我们实验室中发现的WZY02的结构，设计并合成了一系列N-（2-苯氧基）乙基咪唑并[1,2 - a ]吡啶-3-甲酰胺（IPAs），作为新型抗结核药物。结果表明，它们中的许多对药物敏感性MTB菌株H37Rv和耐药性临床分离株均表现出优异的体外抑制活性，且纳摩尔摩尔MIC值低。化合物15b和15d显示出良好的安全性和药代动力学特征，表明它们有望成为未来抗结核药物发现的先导化合物。

  DOI：

  10.1016/j.ejmech.2019.06.038

文献信息

• The Fight against the Influenza A Virus H1N1: Synthesis, Molecular Modeling, and Biological Evaluation of Benzofurazan Derivatives as Viral RNA Polymerase Inhibitors
  作者：Mafalda Pagano、Daniele Castagnolo、Martina Bernardini、Anna Lucia Fallacara、Ilaria Laurenzana、Davide Deodato、Ulrich Kessler、Beatrice Pilger、Lilli Stergiou、Stephan Strunze、Cristina Tintori、Maurizio Botta

  DOI：10.1002/cmdc.201300378

  日期：2014.1

  The influenza RNA polymerase complex, which consists of the three subunits PA, PB1, and PB2, is a promising target for the development of new antiviral drugs. A large library of benzofurazan compounds was synthesized and assayed against influenza virus A/WSN/33 (H1N1). Most of the new derivatives were found to act by inhibiting the viral RNA polymerase complex through disruption of the complex formed

  由PA，PB1和PB2三个亚基组成的流感RNA聚合酶复合物是开发新抗病毒药物的有希望的目标。合成了庞大的苯并呋喃化合物文库，并针对流感病毒A / WSN / 33（H1N1）进行了分析。发现大多数新衍生物通过破坏亚基PA和PB1之间形成的复合物来抑制病毒RNA聚合酶复合物而发挥作用。还进行了对接研究，以阐明PA中PB1结合位点内苯并呋喃类的结合方式，并鉴定参与其作用机理的氨基酸。预测的结合姿势与生物学数据完全一致，为合理开发更有效的PA–PB1抑制剂奠定了基础。
• [EN] SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLO-QUINAZOLINE SUBSTITUÉS À TITRE D'INHIBITEURS DE KINASES
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2012080990A1

  公开（公告）日：2012-06-21

  The present invention relates to substituted pyrazolo[4,3-/h]quinazoline compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular PIM kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.

  本发明涉及替代吡唑并[4,3-/h]喹唑啉化合物，其调节蛋白激酶的活性，因此在治疗由失调的蛋白激酶活性引起的疾病方面具有用处，特别是PIM激酶。本发明还提供了制备这些化合物的方法，包括这些化合物的药物组合物，以及利用这些化合物或含有它们的药物组合物治疗疾病的方法。
• SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS
  申请人：Casuscelli Francesco

  公开号：US20120190678A1

  公开（公告）日：2012-07-26

  The present invention relates to substituted pyrazolo[4,3-h]quinazoline compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular PIM kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.

  本发明涉及替代吡唑并[4,3-h]喹唑啉化合物，其调节蛋白激酶的活性，因此在治疗由失调的蛋白激酶活性引起的疾病方面具有用处，特别是PIM激酶。本发明还提供了制备这些化合物的方法，包括这些化合物的药物组合物，以及利用这些化合物或含有它们的药物组合物治疗疾病的方法。
• [EN] N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION<br/>[FR] DÉGRONS ET DÉGRONIMÈRES À LIAISON N/O POUR LA DÉGRADATION DE PROTÉINES
  申请人：C4 THERAPEUTICS INC

  公开号：WO2018237026A1

  公开（公告）日：2018-12-27

  This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.

  这项发明提供了具有E3泛素连接酶靶向基团（Degrons）的Degronimers，这些Degrons可以与已选择进行体内降解的蛋白质的靶向配体相连接，以及它们的使用方法和组合物，以及它们的制备方法。该发明还提供了可用于治疗由cereblon或Ikaros家族蛋白介导的疾病的Degrons，以及其使用方法和组合物，以及其制备方法。
• Lipid-rich plaque inhibitors
  申请人：——

  公开号：US20030232809A1

  公开（公告）日：2003-12-18

  The present invention provides a lipid-rich plaque regressing agent comprising a compound represented by Formula: 1 in which ring A is a cyclic hydrocarbon or the like; ring B is a heterocyclic ring or the like; each of X and Y is —NR 1 — (in which R 1 is a hydrocarbon or the like); D is a C 1-3 alkylene group or the like; E is —NH— or the like; G is a bond or the like; and Ar is an aryl or the like; D may be taken together with a constituent atom of the ring B to form a ring, and R 4 may be taken together with a constituent atom of the ring B to form a ring.

  本发明提供了一种富含脂质的斑块退行剂，包括一种由式:1所代表的化合物，其中环A是环烃或类似物；环B是杂环或类似物；X和Y中的每一个是—NR1—（其中R1是烃或类似物）；D是C1-3烷基或类似物；E是—NH—或类似物；G是键或类似物；Ar是芳基或类似物；D可以与环B的一个构成原子结合形成环，R4可以与环B的一个构成原子结合形成环。